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Abstract
Diffuse large B-cell lymphoma (DLBCL) is an aggressive subtype of B-cell non–Hodgkin lymphoma (NHL) and accounts
for 30% to 40% of NHL.Molecules targeting nuclear factor-κB (NF-κB) are expected to be of therapeutic value in those
tumorswhereNF-κB seems to play a unique survival role such as activatedB-cell (ABC)-subtypeDLBCL.Wepreviously
generated a rGel/BLyS fusion toxin for receptor-mediated delivery of the rGel toxin specifically to malignant B cells. In
this study, we examined this fusion toxin for its ability to suppress DLBCL growth in vitro and in vivo. rGel/BLyS was
specifically cytotoxic to DLBCL lines expressing all three BLyS receptors and constitutively active NF-κB. Treatment
with rGel/BLyS induced down-regulation of the phosphorylation of inhibitory subunit of NF-κB (IκB-α), inhibition of
NF-κB DNA-binding activity, and accumulation of IκB-α. In agreement with these results, we additionally found that
rGel/BLyS downregulated levels of several NF-κB targets including Bcl-xL, Mcl-1, survivin, and x-chromosome linked
inhibitor-of-apoptosis. Treatment also induced up-regulation of Bax and apoptosis through caspase-3 activation and
poly ADP-ribose polymerase cleavage. Importantly, rGel/BLyS significantly inhibited tumor growth (P< .05) in a DLBCL
xenograft model. Thus, our results indicate that rGel/BLyS is an excellent candidate for the treatment of aggressive
NHLs that are both dependent on NF-κB and are resistant to conventional chemotherapeutic regimens.
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Introduction
Diffuse large B-cell lymphomas (DLBCLs) are highly aggressive B-cell
non–Hodgkin lymphoma (NHL) and account for 40% of NHL. On
the basis of gene expression profiling studies, DLBCLs are subdivided
into three groups: the germinal center B-cell–like (GC)-DLBCL, acti-
vated B-cell–like (ABC)-DLBCL, and primary mediastinal B-cell
lymphoma [1,2]. It has been shown that GC-DLBCL responds favor-
ably to chemotherapy, whereas ABC-DLBCL tends to be refractory to
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chemotherapeutic treatment [1,3,4]. Despite recent advances in the un-
derstanding of the molecular and cellular basis for their pathogenesis,
these tumors are still associated with poor response to treatment and a
fatal outcome [5]. It is now apparent that, to improve the cure rate in
these malignancies, it will be necessary to translate this mechanistic
knowledge into novel, rational, therapeutic modalities.
Nuclear factor-κB (NF-κB) is a transcription factor complex present
in the cytoplasm as an inactive heterotrimer consisting of p50, p65, and
IκB-α subunits. On activation, the IκB kinase phosphorylates IκB,
thereby inducing IκB polyubiquitinylation and subsequent proteolytic
degradation by the 26S proteasome. After IκB degradation, the p50-
p65 heterodimer is released and then able to translocate into the nu-
cleus and to bind to a specific consensus sequence in the DNA [6] and,
subsequently, activate the NF-κB–regulated genes [7]. Several NF-
κB–regulated proteins block programmed cell death, including mem-
bers of the Bcl-2 family, the inhibitor-of-apoptosis (IAP) family, and
GADD45β [8–11].
The NF-κB signaling pathway regulates the survival of normal and
malignant B cells [12]. In particular, constitutive activation of theNF-κB
signaling pathway is crucial for survival of ABC-DLBCL cells but not
GC-DLBCL cells [13,14]. These results suggest that the NF-κB path-
way may be an attractive therapeutic target for ABC-DLBCL express-
ing constitutively active NF-κB.
Successful development of tumor-targeted therapeutic agents is de-
pendent, in part, on both site-specific delivery and on the intracellular
activity of the delivered agent. Recombinant gelonin (rGel) is a type I
ribosomal inactivating plant toxin, and it lacks the ability to bind to the
cell surface and to enter intact cells [15]. However, the rGel toxin has
impressive cytotoxic effects when delivered to target cells using growth
factor ligand as delivery vehicle [16]. Therefore, we recently generated a
fusion toxin rGel/BLyS containing rGel at the N-terminus followed by
a glycine-glycine-glycine-glycine-serine (G4S) peptide tethered to the
B-lymphocyte stimulator (BLyS) molecule for the specific delivery of
rGel toxin to malignant B cells expressing BLyS receptors. In previous
studies, we showed that rGel/BLyS had highly specific cytotoxic activity
against mantle cell lymphoma lines and B chronic lymphocytic leuke-
mia cells expressing the BLyS receptor B-cell–activating factor receptor
(BAFF-R) [17,18].
As an extension of our previous studies, we examined this fusion toxin
for its ability to suppress NHL growth in a DLBCL xenograft model.
Our results show that rGel/BLyS targeting NF-κB signaling pathway
is an excellent candidate for the treatment of aggressive ABC-DLBCL.
Materials and Methods
Materials
The followingmonoclonal and polyclonal antibodieswere used: IκB-α,
Bcl-xL, Bcl-2, Bax, Mcl-1, survivin, x-chromosome linked inhibitor-
of-apoptosis (x-IAP), caspase-3, poly ADP-ribose polymerase (PARP),
and β-actin (Santa Cruz Biotechnology, Santa Cruz, CA); active
caspase-3 (BD Biosciences, San Jose, CA); and phospho-IκB-α (Ser32/
36; Cell Signaling, Beverly, MA). The biotin-conjugated anti–human
transmembrane activator and calcium modulator and cyclophilin li-
gand interactor (TACI), allophycocyanin-conjugated streptavidin, and
phycoerythrin-conjugated anti–human BAFF-R antibodies were pur-
chased from eBioscience (San Diego, CA). The fluorescein isothiocya-
nate (FITC)–conjugated anti–human B-cell maturation antibody
(BCMA) antibody was purchased from Alexis Biochemicals (San Diego,
CA). Cell proliferation kit II (XTT) and in situ cell death detection kit
were purchased from Roche (Mannheim, Germany). The rGel/BLyS
molecule was expressed in Escherichia coli and purified to homogeneity
as previously described [17].
Cell Culture
The eight DLBCL cell lines (SUDHL-4, SUDHL-6, SUDHL-7,
OCI-Ly1, OCI-Ly3, OCI-Ly4, OCI-Ly10, and OCI-Ly19) [1,13,19]
were used for this study. Five GC-DLBCL lines (SUDHL-4, SUDHL-6,
OCI-Ly1, OCI-Ly4, and OCI-Ly19) and one unclassified cell line
(SUDHL-7) were grown in RPMI 1640 medium (ATCC, Manassas,
VA) supplemented with 10% heat-inactivated fetal bovine serum,
100 U/ml penicillin, and 100 μg/ml streptomycin. Two ABC-DLBCL
lines (OCI-Ly3 andOCI-Ly10) were grown in 20% fetal bovine serum.
Cytotoxic Activity of rGel/BLyS against Diffuse Large B-cell
Lymphoma Cells
To examine the comparative half maximal inhibitory concentra-
tion (IC50) values of rGel/BLyS against DLBCL cell lines, SUDHL-4,
SUDHL-6, SUDHL-7, OCI-Ly1, OCI-Ly3, OCI-Ly4, OCI-Ly10, or
OCI-Ly19 cells were seeded (1 × 104 cells per well) in flat-bottom 96-
well microtiter plates (Becton Dickinson Labware, Franklin Lakes, NJ),
and various concentrations of rGel/BLyS or rGel were added in quadru-
plicate wells. After 4 days, cell viability was assessed using the XTTassay
as described previously [17]. Absorbance was measured at 450 nm using
an ELISA reader (Bio-Tek Instruments, Winooski, VT).
For competitive inhibition assays, OCI-Ly3, OCI-Ly10, SUDHL-4,
or SUDHL-6 cells were pretreated with 2 nMof BLyS, 50 nMof BLyS,
10 μg/ml of BAFF-R:Fc, 10 μg/ml of TACI:Fc, or 10 μg/ml of
BCMA:Fc for 2 hours, and then the cells were treated with various
concentrations of free rGel or rGel/BLyS. After 96 hours, cell viability
was assessed using the XTT assay.
Cell Surface Expression of BAFF-R, TACI, and BCMA
on DLBCL Cell Lines
The expression of BAFF-R, BCMA, and TACI in eight DLBCL cell
lines was assessed by flow cytometry. The cells (1 × 106) were washed in
phosphate-buffered saline (PBS), resuspended in ice-cold FACS buffer
(PBS with 1%BSA and 0.01% sodium azide), and then incubated with
the relevant antibodies (BAFF-R, BCMA, or TACI) or isotype control
antibodies for 30 minutes at 4°C. The cells were washed and incubated
with allophycocyanin-conjugated streptavidin for 30 minutes at 4°C,
washed, and analyzed using FACS Aria instrument (BD Biosciences).
Table 1. Cell Surface Expression of BAFF-R, BCMA, TACI, and Comparative IC50 Values of the
rGel/BLyS Fusion Toxin against Diffuse Large B-cell Lymphoma Cell Lines.
Cell Line Subgroup BAFF-R BCMA TACI IC50 (nM) Targeting Index*
rGel rGel/BLyS
OCI-Ly10 ABC ++ ++ +++ 35 0.0007 50,000
OCI-Ly3 ABC ++ +++ ++ 12 0.0008 15,000
SUDHL-4 GC ++ ++ − 350 0.1 3500
SUDHL 6 GC ++ + + 700 5 140
OCI-Ly1 GC + +++ + 700 65 11
OCI-Ly4 GC − +++ − 1900 1400 1
OCI-Ly19 GC − + − 15 11 1
SUDHL-7 U − ++ − 90 120 0.7
The cell surface expression levels of BAFF-R, BCMA, and TACI were normalized to isotype control
antibodies.
−, no expression; +, low expression; ++, intermediate expression; +++, high expression.
ABC indicates activated B cell; GC, germinal center; U , unclassified.
*Targeting index represents IC50 of rGel/IC50 of rGel/BLyS.
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Electrophoretic Mobility Shift Assay
NF-κB–DNA binding were analyzed by electrophoretic mobility
shift assay (EMSA) using a 32P-labeled probe as previously described
[20]. Briefly, nuclear proteins were extracted from 1 × 106 cells after
different treatments. EMSA was performed by incubating 4 μg of nu-
clear extract for 15 minutes at 37°C with 16 fmol of 32P-end-labeled
45-mer double-stranded oligonucleotide (15 μg of protein) containing
the NF-κB binding site (5′-TTGTTACAAGGGACTTTCCGC-
TGGGGACTTTCCAGGGAGGCGTGG-3′) from the human
immunodeficiency virus long terminal repeat. The DNA-protein com-
plex formed was separated from free oligonucleotide on 6.6% native
polyacrylamide gels, and the gel was then dried. The dried gels were
visualized, and NF-κB DNA binding activity was quantitated by a
PhosphorImager Storm 820 (Amersham Biosciences, Piscataway, NJ)
using Imagequant software.
Western Blot Analysis
To examine the effects of rGel/BLyS on the IκB-α, p-IκB-α, Bcl-xL,
Bcl-2, Bax, Mcl-1, survivin, x-IAP, caspase-3, and PARP, OCI-Ly3, or
OCI-Ly10 cells were seeded at 1 × 106 cells per 12-well plate and then
treated with different concentration of rGel/BLyS for 24 hours. For
competitive inhibition assay, OCI-Ly3 cells or OCI-Ly10 cells were
seeded at 1 × 106 cells per 12-well plate and then pretreated with 1 μM
Figure 1. Competitive inhibition of rGel/BLyS binding to several DLBCL lines. For competitive inhibition assay, OCI-Ly3, OCI-Ly10, SUDHL-4,
or SUDHL-6 cellswere seeded (1×104 cells perwell) in flat-bottom96-wellmicrotiter plates andpretreatedwith 2 nMofBLyS, 50nMofBLyS
(A), 10 μg/ml of BAFF-R:Fc, 10 μg/ml of TACI:Fc, or 10 μg/ml of BCMA:Fc (B) for 2 hours, and then rGel or rGel/BLyS was added in quadru-
plicate wells. After 96 hours, cell viability was assessed using the XTT assay. Absorbance was measured at 450 nm using an ELISA reader.
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of BLyS for 2 hours, and then the cells were treated with 1 nM of
rGel/BLyS or medium for 24 hours. Whole-cell extracts or cytoplas-
mic extracts were prepared after wash with PBS and lysed on ice for
20 minutes in 0.3 ml of lysis buffer (10 mM Tris-HCl, pH 8, 60 mM
KCl, 1 mM EDTA, 1 mM DTT, 0.2% NP-40). Cell lysates (50 μg)
were separated by SDS-PAGE (8%-15%) and electrophoretically
transferred to polyvinylidene difluoride (PVDF) membranes (Milli-
pore Corporation, Bedford, MA) overnight at 4°C in transfer buffer
(25 mM Tris-HCl pH 8.3, 190 mM glycine, 20% methanol). The
PVDF membranes were blocked for 1 hour in Tris-buffered saline
containing 5% nonfat milk and then probed with different primary
antibodies for 1 hour at room temperature (RT). After three washes,
themembranes were incubated with horseradish peroxidase–conjugated
goat antimouse/antirabbit or bovine antigoat antibodies (Bio-Rad Labo-
ratories, Hercules, CA) for 1 hour at RT. Detection of immunoreactive
proteins was performed with ECL detection reagent (Amersham Phar-
macia Biotech Inc., Piscataway, NJ). β-Actin was used as a control for
protein loading.
In Vivo Therapy in an ABC-DLBCL Xenograft Model
Animal procedures were performed according to a protocol by the
University of Texas MD Anderson Cancer Center. Male severe com-
bined immunodeficient (SCID) mice (CB17.SCID) were supplied
by Taconic Farms at 3 to 4 weeks of age and were divided into groups
(five mice per group). For in vivo efficacy, we used a DLBCL xenograft
model. Four-week-old male SCID mice were injected with 1 × 107
OCI-Ly10 cells subcutaneously. After the tumors had become estab-
lished (≈250 mm3; 7 weeks after tumor inoculation), the mice were
treated with either PBS or rGel/BLyS twice per week for 2 weeks.
The total dose of rGel/BLyS was 20 mg/kg. Tumor volume was calcu-
lated according to the formula: volume = L ×W ×H , where L = length,
W = width, H = height.
Statistical Analysis
All statistical analyses were done with Microsoft Excel software (Mi-
crosoft, Redmond, WA). Data are presented as mean ± SD. P values
were obtained using 2-tailed t test with 95% confidence interval for
evaluation of the statistical significance compared with the controls.
P < .05 was considered statistically significant.
Immunofluorescence Staining
A histologic study was performed in which groups of five mice bear-
ing OCI-Ly10 tumors were given intraperitoneal injections of either
PBS or rGel/BLyS (20 mg/kg). Twenty-four hours later, the mice were
killed, and tumors were removed. Frozen sections were prepared.
To examine the presence of rGel/BLyS, OCI-Ly10 tumor frozen sec-
tions were dried and then fixed in 3.7% formaldehyde (Sigma, St. Louis,
MO) for 20 minutes at RTand followed by a brief rinse with PBS. Cells
were then permeabilized for 10 minutes in PBS containing 0.2%
Triton X-100, washed three times with PBS, and blocked with PBS
containing 3% bovine serum albumin for 1 hour at RT. Fixed cells were
incubated with anti–rabbit rGel antibody for 2 hours at RT. The slides
were washed three times with PBS and then incubated with anti–rabbit
IgG-FITC–conjugated antibody for 1 hour at RT. After a final wash
step, the slides were mounted inmounting medium and analyzed under
fluorescence microscope.
Detection of Apoptosis
Apoptosis was detected by theTdT-mediated dUTPnick end labeling
(TUNEL) assay. To assess apoptosis, OCI-Ly3 or OCI-Ly10 cells were
seeded at 1 × 106 cells per 12-well plate, and the cells were then treated
with 1 nM of rGel/BLyS or medium for 24 hours. For competitive
Figure 2. Effect of rGel/BLyS on NF-κB binding activity. (A) Consti-
tutive NF-κB activation in DLBCL cell lines. Nuclear extracts from
eight diffuse large B-cell lymphoma lines (OCI-Ly1, OCI-Ly3, OCI-Ly4,
OCI-Ly10, OCI-Ly19, SUDHL-4, SUDHL-6, and SUDHL-7) were pre-
pared and NF-κB binding activity was assessed. (B) Inhibition of
NF-κB binding activity by rGel/BLyS. ABC-DLBCL cell line (OCI-Ly10)
with the highest NF-κB binding activity was seeded (1 × 106 cells per
well) in 12-well plates and incubated with different concentrations
of rGel/BLyS for 24 hours. Nuclear extracts were prepared and sub-
jected to EMSA to assess NF-κB binding activity.
Figure 3. Effects of rGel/BLyS on IκB-α phosphorylation. OCI-Ly3 or
OCI-Ly10 cells were seeded (1 × 106 cells per well) in 12-well plates
and incubatedwith different concentrationsof rGel/BLyS for 24hours.
After treatment, the cells were collected, washed, and lysed in 0.2ml
of lysis buffer. Cytoplasmic extracts (50 μg) were fractionated by 8%
to 15% SDS-PAGE and electrophoretically transferred to PVDFmem-
branes. Themembraneswereblocked, and thenprobedwithanti–IκB-α
antibody, anti–phospho IκB-α (Ser32/36) antibody, or anti–β-actin
antibody. Secondary antibodies conjugated with horseradish per-
oxidase were used to visualize immunoreactive proteins using ECL
detection reagent. β-Actin was used as a control for protein loading.
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inhibition assay, OCI-Ly10 cells were pretreated with 1 μM of BLyS
for 2 hours, and then the cells were treated with 1 nM of rGel/BLyS
or medium for 24 hours. Floating cells were then collected and affixed
to slides using cytospin (Shandon, Pittsburgh, PA). The slides or OCI-
Ly10 tumor frozen sections were dried and then fixed in 3.7% for-
maldehyde (Sigma) for 20 minutes at RT and followed by a brief rinse
with PBS. The slides were then permeabilized for 10 minutes in PBS
containing 0.2% Triton X-100 and 0.1% sodium citrate, washed three
times with PBS, and blocked with PBS containing 3% bovine serum
albumin for 1 hour at RT. Fixed cells were stained with In Situ Cell
Death Detection Kit (Roche). After a final wash step, the slides were
mounted inmounting medium and analyzed under fluorescence micro-
scope. Apoptotic cells were counted in randomly selected fields (×200)
and expressed as a percentage.
Results
rGel/BLyS Is Selectively Toxic for DLBCL Cells Expressing the
BLyS Receptors BAFF-R, BCMA, and TACI
To assess the efficacy of the fusion toxin rGel/BLyS in DLBCL, the
cytotoxic effect of rGel/BLyS fusion toxin or free rGel and the expression
of BLyS receptors were analyzed in eight DLBCL cell lines (Table 1).
The ratio of IC50 values of rGel to rGel/BLyS (targeting index) was
calculated for each cell line. This ratio represents the ability of the BLyS
component of the rGel/BLyS to mediate delivery of the rGel toxin
component to the target cell cytoplasm and normalizes for the inherent
cellular sensitivity to the rGel toxin. Of all the tumor lines tested, two
ABC-DLBCL lines (OCI-Ly3 and OCI-Ly10) were found to be the
most sensitive to the rGel/BLyS fusion toxin (targeting index > 14,000)
and expressed high levels of BAFF-R, BCMA, and TACI. Among five
GC-DLBCL lines (SUDHL-4, SUDHL-6, OCI-Ly1, OCI-Ly4, and
OCI-Ly19), two GC-DLBCL cell lines (SUDHL-4 and SUDHL-6)
showed intermediate sensitivity to this fusion toxin (targeting index >
130) and expressed comparable amount of BAFF-R. However, three
GC-DLBCL cell lines (OCI-Ly1, OCI-Ly4, and OCI-Ly19) showed
less sensitivity to this fusion toxin. OCI-Ly1 cell line expressed relatively
low levels of BAFF-R (targeting index = 11), whereas OCI-Ly4 and
OCI-Ly19 did not express BAFF-R and TACI (targeting index = 1).
The SUDHL-7 DLBCL cell line that has not been classified under
either subgroup showed relatively lower sensitivity to this fusion toxin
(targeting index = 0.7) and did not express either BAFF-R or TACI.
Our results showed that rGel/BLyS was specifically cytotoxic to the
Figure 4. Effects of rGel/BLyS on NF-κB–regulated proteins. OCI-Ly3 or OCI-Ly10 cells were seeded (1 × 106 cells per well) in 12-well plates
and pretreated with 1 μMof BLyS for 2 hours and then treated with 1 nM rGel/BLyS or medium for 24 hours. After treatment, the cells were
collected, washed, and lysed in 0.2 ml of lysis buffer. Whole-cell extracts (50 μg) were fractionated by 8% to 15% SDS-PAGE and electro-
phoretically transferred to PVDFmembranes. Themembraneswere blocked and then probedwith various antibodies. Secondary antibodies
conjugated with horseradish peroxidase were used to visualize immunoreactive proteins using ECL detection reagent. β-Actin was used as
a control for protein loading.
Figure 5. Effects of rGel/BLyS on apoptotic pathways. (A) Microscopic appearance of OCI-Ly3 or OCI-Ly10 cells after treatment. OCI-Ly3
or OCI-Ly10 cells were treated with 1 nM rGel/BLyS or media. After 24 hours, the cells were assayed for apoptosis by TUNEL staining.
(B) Competitive inhibition of rGel/BLyS binding by pretreatment with BLyS. OCI-Ly10 cells were seeded (1 × 106 cells per well) in 12-well
plates and pretreated with 1 μMof BLyS for 2 hours and then treatedwith 1 nM rGel/BLyS ormedium for 24 hours. After 24 hours, the cells
were assayed for apoptosis by TUNEL staining. Apoptotic cells were counted in randomly selected fields (×200) and expressed as a per-
centage of total cells counted. (C) Effects of rGel/BLyS on apoptotic pathways. OCI-Ly3 or OCI-Ly10 cells were seeded at 1 × 106 cells per
12-well plate and treated with different concentrations of rGel/BLyS for 24 hours or pretreated with 1 μM of BLyS for 2 hours and then
treated with 1 nM rGel/BLyS or medium for 24 hours. After treatment, the cells were collected, washed, and lysed in 0.2 ml of lysis buffer.
Whole-cell extracts (50 μg)were fractionated by 8% to 15%SDS-PAGE and electrophoretically transferred to PVDFmembranes. Themem-
branes were blocked and then probed with various antibodies. Secondary antibodies conjugated with horseradish peroxidase were used
to visualize immunoreactive proteins using ECL detection reagent. β-Actin was used as a control for protein loading.
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ABC-DLBCL cells that express high levels of all three BLyS receptors
(BAFF-R, BCMA, and TACI) but not GC-DLBCL cells that did not
express BAFF-R and TACI.
The Cytotoxic Effect of rGel /BLyS Is Mediated through Direct
Binding to BLyS Receptors BAFF-R, BCMA, and TACI
The biological effects of BLyS are mediated by three cell surface re-
ceptors designated BAFF-R, TACI, and BCMA [21–23]. Therefore, we
examined whether pretreatment with BLyS might partially block the
rGel/BLyS–mediated cytotoxicity in four DLBCL lines (OCI-Ly3,
OCI-Ly10, SUDHL-4, and SUDHL-6). We found that pretreatment
of BLyS showed a shift in the dose-response curve in rGel/BLyS–treated
DLBCL lines but not with treatment of rGel-treated cells (Figure 1A).
The constructs BAFF-R:Fc, TACI:Fc, or BCMA:Fc decoy receptors
can bind to BLyS, prevent the binding of BLyS to their receptors, and
inhibit BLyS-mediated B-cell activation. Therefore, we next examined
whether pretreatment with various decoy receptors might partially
block the rGel/BLyS–mediated cytotoxicity in two ABC-DLBCL lines
(OCI-Ly3 and OCI-Ly10). We found that pretreatment of BAFF-R:
Fc, TACI:Fc, or BCMA:Fc decoy receptors completely blocked the
rGel/BLyS–mediated cytotoxicity in ABC-DLBCL lines (Figure 1B).
These data demonstrate that the cytotoxic effects of rGel/BLyS seem
to be mediated through direct binding of fusion toxin to cellular BLyS
receptors BAFF-R, TACI, and BCMA.
rGel/BLyS Inhibits Constitutive NF-κB Activity in
ABC-DLBCL Cells
NF-κB activity is critical for normal B-cell development and survival.
In addition, BLyS signals have been shown to modulate the activity of
this transcription factor complex. Therefore, we sought to determine
the NF-κB binding activity in DLBCL cell lines and whether there
was a correlation with rGel/BLyS–dependent cytotoxicity. As shown
in Figure 2A, NF-κB was found to be constitutively activated in two
ABC-DLBCL cell lines (OCI-Ly3 and OCI-Ly10) that are very sensi-
tive to rGel/BLyS. However, five GC-DLBCL cell lines (OCI-Ly1,
OCI-Ly4, OCI-Ly19, SUDHL-4, and SUDHL-6) and one unclassified
DLBCL cell line (SUDHL-7) that are less sensitive to this fusion toxin
showed low levels of NF-κB binding activity. Therefore, basal levels of
NF-κB did not predict sensitivity to rGel/BLyS.
To evaluate whether rGel/BLyS showed an inhibitory effect on con-
stitutive NF-κB activation in DLBCL cells, we performed EMSA using
nuclear extracts from rGel/BLyS–treated OCI-Ly10 cells, which dem-
onstrated the highest NF-κB-DNA binding activity and which are very
sensitive to rGel/BLyS. Data clearly showed that this fusion toxin
suppressed constitutive NF-κB activation in a dose-dependent man-
ner (Figure 2B).
rGel/BLyS Inhibits IκB-α Phosphorylation and IκB-α
Degradation in ABC-DLBCL Cells
The degradation of IκB-α is required forNF-κB activation [7] and the
proteolytic degradation of IκB-α is known to first require phosphory-
lation at serine residues 32 and 36. We next determined whether in-
hibition of NF-κB activation by rGel/BLyS was due to inhibition of
IκB-α phosphorylation or IκB-α degradation. We found that rGel/
BLyS treatment results in an inhibition in the levels of phospho IκB-α.
As assessed byWestern blot analysis, this led to a marked accumulation
of IκB-α in the OCI-Ly10 cell line but only a very modest change in
the IκB-α content of the OCI-Ly3 line (Figure 3).
rGel /BLyS Suppresses NF-κB–Regulated Proteins in
ABC-DLBCL Cells
NF-κB regulates the expression of several antiapoptotic proteins in-
cluding IAP1, IAP2, Bcl-2, Bcl-xL, x-IAP, c–FLICE-like inhibitory pro-
tein, and survivin.Hence, we examinedwhether rGel/BLyS canmodulate
NF-κB target gene products by Western blot analysis in ABC-DLBCL
cells. As shown in Figure 4, rGel/BLyS specifically inhibited the expres-
sion of Bcl-xL, Mcl-1, survivin, and x-IAP but not Bcl-2. We also found
that rGel/BLyS induced the expression of Bax. Pretreatment of these
ABC-DLBCL lines with BLyS for 2 hours partially blocked rGel/BLyS–
mediated down-regulation of these NF-κB targets and up-regulation
of Bax.
Treatment with rGel /BLyS Induces Apoptosis in
ABC-DLBCL Cells
To determine whether the cytotoxic effect of rGel/BLyS was asso-
ciated with apoptosis, two ABC-DLBCL lines (OCI-Ly3 and OCI-
Ly10) were examined for apoptosis by TUNEL staining. As shown in
Figure 5A, rGel/BLyS–treated OCI-Ly3 and OCI-Ly10 cells showed
34% and 37%of apoptotic cells, respectively.We also examined whether
pretreatment with BLyS can block rGel/BLyS–induced apoptosis in
OCI-Ly10 cells. In concert with the data in Figure 4, pretreatment
with BLyS completely blocked the proapoptotic effect of rGel/BLyS
fusion toxin (Figure 5B).
The caspase proteins are known to be central mediators of the apop-
totic effects of TNFand other cytokines. To determine whether caspase-3
was activated in ABC-DLBCL cells during rGel/BLyS–induced cell
death, we examined the cleavage of caspase-3 and its substrate PARP.
Exposure of cells to rGel/BLyS resulted in cleavage of caspase-3 and
also induced PARP cleavage in ABC-DLBCL cell lines (OCI-Ly3 and
OCI-Ly10), suggesting that the cytotoxic effects of this fusion toxin
Figure 6. In vivo efficacy of rGel/BLyS in a DLBCL xenograft model.
For the ABC-DLBCL xenograft model, 4-week-old male SCID mice
were injectedwith 1×107OCI-Ly10 cells subcutaneously. After the
tumors had become established (≈250 mm3; 7 weeks after tumor in-
oculation), the mice were treated with either PBS or rGel/BLyS twice
per week for 2 weeks. The total dose of rGel/BLyS was 20 mg/kg.
Points, mean tumor volume; bars, SD. X axis, arrows, treatment.
*P < .05, Student’s t test.
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seemed to bemediated, at least in part, by caspase-3 and PARP cleavage.
Pretreatment with BLyS partially blocked rGel/BLyS–induced cleavage
of caspase-3 and PARP (Figure 5C).
rGel /BLyS Inhibits Tumor Growth in an ABC-DLBCL
Xenograft Model
To investigate the potential in vivo efficacy of rGel/BLyS, we used a
DLBCL xenograft model. SCID mice were subcutaneously inoculated
with OCI-Ly10 cells and tumors were allowed to establish for 7 weeks
before treatment (≈250mm3). Tumor volume in the PBS-treated group
increased from 258 to 1305mm3 during the 13-day observation period,
whereas tumor volume in the rGel/BLyS–treated group (20 mg/kg,
intraperitoneally, twice weekly for 2 weeks) showed no significant
increase on tumor growth during the course of the experiment (from
260 to 226 mm3). Compared with controls, treatment with rGel/BLyS
was shown to result in an 83% reduction in tumor volume (1305 vs
Figure 7. Localization of rGel/BLyS in tumor xenografts. (A) Detection of rGel/BLyS in ABC-DLBCL tumor. To examine the presence of
rGel/BLyS, OCI-Ly10 tumor frozen sections were dried and then fixed in 3.7% formaldehyde for 20 minutes at RT and followed by a brief
rinse with PBS. Tumor sections were then permeabilized, washed, blocked, and incubated with anti–rabbit rGel antibody for 2 hours at RT.
The slides were washed three times with PBS and then incubated with anti–rabbit IgG-FITC–conjugated antibody for 1 hour at RT. After a
final wash step, the slidesweremounted inmountingmedium and analyzed under fluorescencemicroscope. (B) Detection of apoptosis in
ABC-DLBCL tumor. Apoptosis was detected by the TUNEL assay.
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226 mm3). The rGel/BLyS fusion toxin significantly inhibited tu-
mor growth in SCID mice bearing ABC-DLBCL xenografts (P < .05;
Figure 6).
Internalized rGel/BLyS Induces Apoptosis in
ABC-DLBCL Xenografts
We examined whether the rGel/BLyS fusion toxin can internalize
into OCI-Ly10 tumors in vivo. As shown in Figure 7A, the rGel compo-
nent of rGel/BLyS fusion toxin was shown to accumulate in OCI-Ly10
tumors 24 hours after the last intraperitoneal administration. This
demonstrates that rGel/BLyS is capable of efficient localization in tu-
mors. We next examined whether rGel/BLyS can induce apoptosis in
OCI-Ly10 tumors. As shown in Figure 7B, there was a significant in-
crease in apoptosis (as assessed by TUNEL staining) in tumors from
mice treated with rGel/BLyS.
Discussion
The growth factor BLyS is crucial for B-cell survival, and the biological
effects of BLyS are mediated by three cell surface receptors designated
BAFF-R, TACI, and BCMA [21–23]. The BLyS ligand is expressed on
multiple types of malignant B cells [24–26]. The BAFF-receptor
(BAFF-R) is the most abundantly expressed in approximately 80% of
mantle cell lymphoma and in approximately 44% of DLBCL [27].
Therefore, it has been suggested that targeting BLyS and its receptors
may disrupt this important autocrine growth loop and may have value
in designing therapeutic approaches for B-cell malignancies.
In this study, we evaluated the cytotoxic activity of rGel/BLyS against
DLBCL lines. Of the eight DLBCL lines studied, two ABC-DLBCL
lines (OCI-Ly3 andOCI-Ly10) expressing all three BLyS receptors were
found to be the most sensitive to the fusion toxin (targeting index =
15,000 and 50,000), whereas nontargeted rGel itself showed no specific
cytotoxic activity against DLBCL lines. As shown previously [16–18],
this suggests that the rGel component has impressive cytotoxic effects
when delivered to cells using growth factor ligands. Our results demon-
strate that BLyS has the potential to serve as an excellent targeting ligand
for the specific delivery of rGel toxin to DLBCL cells expressing all three
BLyS receptors.
Novak et al. [26] reported thatDLBCL cells expressed BAFF-R but not
BCMA. Paterson et al. [28] reported that SUDHL-4 and SUDHL-6
lines expressed BAFF-R but not OCI-Ly3 and OCI-Ly10 lines.
However, our results showed that BAFF-R was expressed in approx-
imately 62.5% of DLBCL lines tested (OCI-Ly3, OCI-Ly10,
SUDHL-4, and SUDHL-6), whereas BCMA and TACI were ex-
pressed in approximately 100% and 50% of the cell lines tested, re-
spectively. We also observed that OCI-Ly3, OCI-Ly10, SUDHL-4,
and SUDHL-6 cell line expressed similar levels of BAFF-R.
The transcription factor NF-κB has been shown to regulate the
expression of a number of genes whose products are involved in tu-
morigenesis [7]. A recent gene profiling study has shown that the genes
involved in TNF and NF-κB signaling pathways are overexpressed in
ABC-DLBCL [1]. NF-κB is known to be responsible, in part, for me-
diating neoplastic B-cell growth and cell survival [29,30]. Dominant-
negative inhibitors of the NF-κB pathway were shown to induce cell
death of ABC-DLBCL cells but not GC-DLBCL cells [13]. The IκB
kinase inhibitor PS-1145 was found to be selectively toxic for ABC-
DLBCL cell lines but not for GC-DLBCL lines [14]. Transfection
of DLBCL cells with siBLyS RNA was found to reduce NF-κB
DNA binding activity [31]. These results suggest that inhibition of
NF-κB is expected to be of therapeutic value in tumors such as
ABC-DLBCL, where NF-κB seems to play a unique survival role.
The rGel toxin is an extremely potent inhibitor of protein synthesis,
similar in action to ricin. Ricin has been shown to induce NF-κB ac-
tivation and TNF production in human airway epithelial cells [32]. In
contrast, treatment with the rGel/BLyS fusion toxin resulted in the
inhibition of constitutive NF-κB activation in ABC-DLBCL lines, al-
though rGel has similar enzymatic activity to ricin. Therefore, our re-
sults indicate that the rGel toxin is an ideal payload to target NHL
expressing constitutively active NF-κB.
Accumulation of rGel/BLyS and apoptosis of tumor cells were ob-
served 24 hours after the last intraperitoneal administration of rGel/
BLyS to SCID mice bearing OCI-Ly10 cells. Importantly, rGel/BLyS
was shown to significantly inhibit tumor growth (P < .05) in ABC-
DLBCL (OCI-Ly10) xenograft model.We observed that themaximum
tolerated dose of rGel/BLyS for intraperitoneal administration using a
twice per week for 12 week schedule was more than 60 mg/kg, whereas
the maximum tolerated dose of rGel/BLyS for intravenous adminis-
tration was 7.5 mg/kg for twice per week for a 2-week schedule in
Balb/c mice (data not shown).
Taken together, our results demonstrate that the rGel/BLyS fusion
toxin was selectively toxic for ABC-DLBCL cells both in vitro and in vivo
and indicate that this fusion toxin is an excellent candidate for the treat-
ment of aggressiveNHLs that are both dependent onNF-κB signals and
resistant to conventional chemotherapeutic regimens.
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